[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,230,463
  • Shares Outstanding, K 118,613
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 649 M
  • EBITDA $ 741 M
  • 60-Month Beta 0.84
  • Price/Sales 6.68
  • Price/Cash Flow 16.47
  • Price/Book 42.40

Options Overview Details

View History
  • Implied Volatility 41.66% (+1.43%)
  • Historical Volatility 29.80%
  • IV Percentile 84%
  • IV Rank 48.67%
  • IV High 52.70% on 08/05/25
  • IV Low 31.19% on 01/20/26
  • Expected Move (DTE 28) 6.02 (7.44%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 277
  • Volume Avg (30-Day) 420
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 10,332
  • Open Int (30-Day) 11,362
  • Expected Range 74.82 to 86.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.73
  • Number of Estimates 2
  • High Estimate $1.73
  • Low Estimate $1.72
  • Prior Year $1.47
  • Growth Rate Est. (year over year) +17.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.72 +15.94%
on 06/24/26
82.26 -1.73%
on 07/07/26
+11.22 (+16.12%)
since 06/23/26
3-Month
62.38 +29.59%
on 05/01/26
82.26 -1.73%
on 07/07/26
+14.25 (+21.40%)
since 04/23/26
52-Week
57.67 +40.16%
on 07/29/25
82.26 -1.73%
on 07/07/26
+22.28 (+38.05%)
since 07/23/25

Most Recent Stories

More News
Halozyme to Report Second Quarter 2026 Financial and Operating Results

SAN DIEGO , July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday,...

HALO : 80.84 (+3.88%)
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Agreement provides Incyte the rights to develop and commercialize ENHANZE ® with its mutCALR development program and an option to nominate up to two additional targets

INCY : 116.69 (+0.78%)
HALO : 80.84 (+3.88%)
1 Value Stock Worth Investigating and 2 Facing Headwinds

1 Value Stock Worth Investigating and 2 Facing Headwinds

ASLE : 6.18 (+1.48%)
NX : 18.26 (-1.14%)
HALO : 80.84 (+3.88%)
2 Reasons to Like HALO and 1 to Stay Skeptical

2 Reasons to Like HALO and 1 to Stay Skeptical

HALO : 80.84 (+3.88%)
1 Surging Stock for Long-Term Investors and 2 We Brush Off

1 Surging Stock for Long-Term Investors and 2 We Brush Off

ACT : 45.97 (+0.44%)
HALO : 80.84 (+3.88%)
CLMT : 42.82 (-2.99%)
2 Profitable Stocks Worth Your Attention and 1 We Question

2 Profitable Stocks Worth Your Attention and 1 We Question

ADM : 86.35 (-1.11%)
UPST : 27.59 (-3.67%)
HALO : 80.84 (+3.88%)
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

SAN DIEGO , June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact...

HALO : 80.84 (+3.88%)
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

HALO : 80.84 (+3.88%)
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

HALO : 80.84 (+3.88%)
3 Growth Stocks Set to Flourish

3 Growth Stocks Set to Flourish

CECO : 79.59 (-2.73%)
TOST : 28.40 (-2.77%)
HALO : 80.84 (+3.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 86.78
2nd Resistance Point 83.99
1st Resistance Point 82.41
Last Price 80.84
1st Support Level 78.04
2nd Support Level 75.25
3rd Support Level 73.67

See More

52-Week High 82.26
Last Price 80.84
Fibonacci 61.8% 72.87
Fibonacci 50% 69.97
Fibonacci 38.2% 67.07
52-Week Low 57.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.